Despite significant improvements in the quality and efficacy of haemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients.

Today, almost every other dialysis patient dies from cardiovascular complications. Fresenius Medical Care is supporting nephrologists worldwide in reducing their patients’ risks for cardiovascular morbidity and mortality. Innovative membranes like Fresenius Polysulfone and Helixone, modern monitoring devices like the Blood Volume Monitor, the Blood Temperature Monitor and Online Clearance Monitoring (OCM ), ultrapure dialysis fluid prepared with DIASAFE plus and modern ONLINE haemodiafiltration systems support the reduction of CVD risk factors. Moreover, one of our major goals in the coming years is the development and implementation of innovative new therapies and products in Nephrology that further improve the cardiovascular prognosis of dialysis patients. The quality and purity of the dialysis fluid are of major concern in modern-day renal replacement therapies, as large volumes of dialysis fluid come into contact with the patient’s bloodstream during each treatment. Bacterial endotoxins present in contaminated dialysis fluid may elicit undesirable acute reactions and influence the long-term outcome of patients on chronic haemodialysis. Although water used for the production of dialysis fluid is treated by a series of purification steps, it still may not meet the stringent requirements on bacterial contamination levels laid down by various regulatory bodies. By the application of special filters that are highly efficient in retaining bacterial contamination, the required purity grades of dialysis fluid can be achieved easily. The DIASAFE plus filter, located at the end of the water treatment chain, ensure the safe production of ultrapure dialysis fluid. This is attributed to the excellent endotoxin retention capabilities of its Fresenius Polysulfone fibres.

Despite significant improvements in the quality and efficacy of haemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients.

Today, almost every other dialysis patient dies from cardiovascular complications. Fresenius Medical Care is supporting nephrologists worldwide in reducing their patients’ risks for cardiovascular morbidity and mortality. Innovative membranes like Fresenius Polysulfone and Helixone, modern monitoring devices like the Blood Volume Monitor, the Blood Temperature Monitor and Online Clearance Monitoring (OCM ), ultrapure dialysis fluid prepared with DIASAFE plus and modern ONLINE haemodiafiltration systems support the reduction of CVD risk factors. Moreover, one of our major goals in the coming years is the development and implementation of innovative new therapies and products in Nephrology that further improve the cardiovascular prognosis of dialysis patients. The quality and purity of the dialysis fluid are of major concern in modern-day renal replacement therapies, as large volumes of dialysis fluid come into contact with the patient’s bloodstream during each treatment. Bacterial endotoxins present in contaminated dialysis fluid may elicit undesirable acute reactions and influence the long-term outcome of patients on chronic haemodialysis. Although water used for the production of dialysis fluid is treated by a series of purification steps, it still may not meet the stringent requirements on bacterial contamination levels laid down by various regulatory bodies. By the application of special filters that are highly efficient in retaining bacterial contamination, the required purity grades of dialysis fluid can be achieved easily. The DIASAFE plus filter, located at the end of the water treatment chain, ensure the safe production of ultrapure dialysis fluid. This is attributed to the excellent endotoxin retention capabilities of its Fresenius Polysulfone fibres.